Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Assets: 2012-2024

Historic Assets for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $1.7 billion.

  • Agios Pharmaceuticals' Assets fell 22.66% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 22.66%. This contributed to the annual value of $1.7 billion for FY2024, which is 77.48% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Assets stood at $1.7 billion for FY2024, which was up 77.48% from $937.1 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Assets ranged from a high of $1.7 billion in FY2024 and a low of $853.0 million during FY2020.
  • Its 3-year average for Assets is $1.3 billion, with a median of $1.2 billion in 2022.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Assets declined by 24.35% in 2023, and later surged by 77.48% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Assets (Yearly) stood at $853.0 million in 2020, then surged by 68.56% to $1.4 billion in 2021, then declined by 13.84% to $1.2 billion in 2022, then fell by 24.35% to $937.1 million in 2023, then surged by 77.48% to $1.7 billion in 2024.